Gamelin Erick 4

What Happened
Erick Gamelin, Chief Development Officer of Acrivon Therapeutics (ACRV), had 471 restricted stock units (RSUs) withheld by the issuer to satisfy mandatory tax withholding upon vesting. The withheld shares were valued at $1.63 each, totaling approximately $768. This is a routine tax-withholding disposition rather than an open-market sale or purchase.

Key Details

• Transaction date: 2026-02-14; Filing date: 2026-02-18 (Form 4 accession 0000905148-26-000936).
• Action: Tax withholding upon RSU vesting (transaction code F).
• Shares withheld/disposed: 471 shares at $1.63 per share; total ~$768.
• Footnote: F1 — "Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."
• Shares owned after transaction: Not specified in the provided excerpt.
• Filing timeliness: No late-filing flag provided in the excerpt.

Context
Tax-withholding dispositions are common when RSUs vest and do not necessarily indicate the insider is selling stock for investment reasons. This transaction reflects a mandatory withholding to cover taxes rather than a discretionary sale or purchase.